Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeming Mo

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Cancer|August 5, 2017
The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T CellsZeming Mo, Peixin Du, Guoping Wang, et al.
Cancer Medicine|December 6, 2023
Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experienceZeming Mo, Yaotiao Deng, Yiwen Bao, et al.
Oral Oncology|August 23, 2015
Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysisBinglan Zhang, Zeming Mo, Wei Du, et al.
Medcomm|January 6, 2026
Melanoma: Pathogenesis and Targeted TherapyYang Fu, Jie Liu, Zeming Mo, et al.
International Immunopharmacology|September 28, 2023
Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanomaZeming Mo, Jie Liu, Jinyan Zhang, et al.
Frontiers in Pharmacology|February 8, 2024
Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)Yiwen Bao, Jiaju Chen, Luting Duan, et al.
Journal of Cancer Research and Clinical Oncology|January 31, 2024
Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapyAiping Zheng, Jie Liu, Zijing Liu, et al.
Frontiers in Immunology|December 2, 2024
Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023Yiwen Bao, Zeming Mo, Shuang Wang, et al.
Frontiers in Immunology|January 2, 2026
Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistanceZeming Mo, Honglian Jiang, Lei Zhou, et al.
International Journal of Radiation Oncology, Biology, Physics|April 26, 2020
Low-Dose Radiation Therapy Promotes Radiation Pneumonitis by Activating NLRP3 InflammasomeXiaoyu Li, Youling Gong, Dan Li, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Cancer|August 5, 2017
The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T CellsZeming Mo, Peixin Du, Guoping Wang, et al.
Cancer Medicine|December 6, 2023
Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experienceZeming Mo, Yaotiao Deng, Yiwen Bao, et al.
Oral Oncology|August 23, 2015
Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysisBinglan Zhang, Zeming Mo, Wei Du, et al.
Medcomm|January 6, 2026
Melanoma: Pathogenesis and Targeted TherapyYang Fu, Jie Liu, Zeming Mo, et al.
International Immunopharmacology|September 28, 2023
Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanomaZeming Mo, Jie Liu, Jinyan Zhang, et al.
Frontiers in Pharmacology|February 8, 2024
Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)Yiwen Bao, Jiaju Chen, Luting Duan, et al.
Journal of Cancer Research and Clinical Oncology|January 31, 2024
Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapyAiping Zheng, Jie Liu, Zijing Liu, et al.
Frontiers in Immunology|December 2, 2024
Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023Yiwen Bao, Zeming Mo, Shuang Wang, et al.
Frontiers in Immunology|January 2, 2026
Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistanceZeming Mo, Honglian Jiang, Lei Zhou, et al.
International Journal of Radiation Oncology, Biology, Physics|April 26, 2020
Low-Dose Radiation Therapy Promotes Radiation Pneumonitis by Activating NLRP3 InflammasomeXiaoyu Li, Youling Gong, Dan Li, et al.
Pageof 2